Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
Nadine Leonie de BoerJob P van KootenJacobus W A BurgerCornelis VerhoefJoachim G J V AertsEva V E MadsenPublished in: BMJ open (2019)
NTR7060. EudraCT: 2017-000897-12; Pre-Results.
Keyphrases
- phase ii
- open label
- clinical trial
- dendritic cells
- phase iii
- minimally invasive
- coronary artery bypass
- study protocol
- early stage
- phase ii study
- regulatory t cells
- surgical site infection
- locally advanced
- immune response
- double blind
- placebo controlled
- metastatic renal cell carcinoma
- coronary artery disease
- percutaneous coronary intervention
- acute coronary syndrome
- rectal cancer